SMS Pharmaceuticals Quarterly Results for Trading Insights
In Mar 2026, SMS Pharmaceuticals (SMSPHARMA) reported revenue ₹241 Cr and net profit ₹33 Cr — revenue -3.6% YoY. Also explore SMS Pharmaceuticals stock price data download to track price trends across different timeframes.
SMSPHARMA Quarterly Results — Revenue, Profit & EPS Highlights
SMS Pharmaceuticals latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. For annual financials, live price and key ratios, visit SMSPHARMA stock price BSE.
- Revenue of ₹241 Cr in Mar 2026 (-1.2% vs Sept 2025, -3.6% vs Mar 2025)
- Net Profit of ₹33 Cr in Mar 2026 (+32.0% vs Sept 2025, +65.0% vs Mar 2025)
- EBITDA of ₹43 Cr in Mar 2026 (-14.0% vs Sept 2025)
- Operating Margin of 17.0% in Mar 2026 (-3.0pp vs Sept 2025)
- Earnings Per Share of ₹3.58 in Mar 2026 (+26.1% vs Sept 2025)
SMS Pharmaceuticals Quarterly Results — Revenue, EBITDA, Net Profit & EPS
SMSPHARMA quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Mar 2026 | Sept 2025 | Mar 2025 | Jun 2025 | Dec 2025 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 241 | 244 | 250 | 197 | 214 | -1.2% | -3.6% |
| Net Profit (₹ Cr) | 33 | 25 | 20 | 21 | 24 | - | - |
| EBITDA (₹ Cr) | 43 | 50 | 42 | 40 | 47 | - | - |
| EPS (₹) | 3.58 | 2.84 | 2.40 | 2.31 | 2.59 | - | - |
| Operating Margin (%) | 17.0% | 20.0% | 16.0% | 20.0% | 21.0% | - | - |
SMSPHARMA Share Price Trend — 1-Year Movement Across Quarterly Results
SMS Pharmaceuticals 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. Browse SMSPHARMA financial statements for revenue, profit, balance sheet and cash flow data.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
SMSPHARMA vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
SMS Pharmaceuticals latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Mar 2026 |
₹469,405.89 Cr | 1941.1 | 15,018 | 2,710 | +1.0% | +11.8% | 18.0% | 171.8 |
|
Divis Laboratories
Mar 2026 |
₹194,269.91 Cr | 7248.5 | 2,986 | 751 | +4.4% | +11.8% | 25.2% | 256.0 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹191,454.40 Cr | 4961.5 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 431.1 |
|
Zydus Life Science
Mar 2026 |
₹115,616.29 Cr | 1108.7 | 7,569 | 1,341 | +23.1% | +18.8% | 17.7% | 87.6 |
|
Cipla
Mar 2026 |
₹114,318.19 Cr | 1410.6 | 6,612 | 543 | -14.3% | -4.0% | 8.2% | 205.3 |
All amounts in ₹ Crores